STEVENSON, Md., Sept. 05, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Acacia Communications, Inc. (NASDAQ:ACIA) (“Acacia” or the “Company”) securities during the period between August 11, 2016, and July 13, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until October 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Acacia securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Acacia’s manufacturing and quality control processes were deficient and were likely to disrupt the Company’s manufacturing and impact revenues.
According to the complaint, following a July 14, 2017 announcement that the Company’s profit and revenue were short of projections because of quality issues identified at one of their three contract manufacturers, the value of Acacia shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Acacia securities purchased on or after August 11, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Italy Fines Apple €98.6 Million Over App Store Dominance
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



